MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) Stock Competitors & Peer Comparison

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, LLY has a market cap of 1.2T. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while LLY trades at $1,231.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas LLY's P/E ratio is 39.10. In terms of profitability, MIRA's ROE is -1.41%, compared to LLY's ROE of +0.93%. Regarding short-term risk, MIRA is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check LLY's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, JNJ has a market cap of 630.6B. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while JNJ trades at $261.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas JNJ's P/E ratio is 24.39. In terms of profitability, MIRA's ROE is -1.41%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, MIRA is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check JNJ's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, ABBV has a market cap of 437.9B. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while ABBV trades at $247.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas ABBV's P/E ratio is 24.32. In terms of profitability, MIRA's ROE is -1.41%, compared to ABBV's ROE of -1.37%. Regarding short-term risk, MIRA is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check ABBV's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, MRK has a market cap of 323.3B. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while MRK trades at $130.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas MRK's P/E ratio is 40.78. In terms of profitability, MIRA's ROE is -1.41%, compared to MRK's ROE of +0.07%. Regarding short-term risk, MIRA is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check MRK's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, NVS has a market cap of 298B. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while NVS trades at $156.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas NVS's P/E ratio is 18.04. In terms of profitability, MIRA's ROE is -1.41%, compared to NVS's ROE of +0.30%. Regarding short-term risk, MIRA is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check NVS's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, AZN has a market cap of 251.1B. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while AZN trades at $161.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas AZN's P/E ratio is 17.48. In terms of profitability, MIRA's ROE is -1.41%, compared to AZN's ROE of +0.22%. Regarding short-term risk, MIRA is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check AZN's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, AMGN has a market cap of 221.8B. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while AMGN trades at $417.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas AMGN's P/E ratio is 18.37. In terms of profitability, MIRA's ROE is -1.41%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, MIRA is more volatile compared to AMGN. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check AMGN's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, NVO has a market cap of 212B. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while NVO trades at $47.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas NVO's P/E ratio is 11.87. In terms of profitability, MIRA's ROE is -1.41%, compared to NVO's ROE of +0.59%. Regarding short-term risk, MIRA is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check NVO's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, GILD has a market cap of 165.2B. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while GILD trades at $133.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas GILD's P/E ratio is -341.18. In terms of profitability, MIRA's ROE is -1.41%, compared to GILD's ROE of -0.16%. Regarding short-term risk, MIRA is more volatile compared to GILD. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check GILD's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, PFE has a market cap of 154.2B. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while PFE trades at $27.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas PFE's P/E ratio is 8.87. In terms of profitability, MIRA's ROE is -1.41%, compared to PFE's ROE of +0.05%. Regarding short-term risk, MIRA is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check PFE's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, BMY has a market cap of 132.5B. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while BMY trades at $64.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas BMY's P/E ratio is 10.94. In terms of profitability, MIRA's ROE is -1.41%, compared to BMY's ROE of +0.47%. Regarding short-term risk, MIRA is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check BMY's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, GSK has a market cap of 104.6B. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while GSK trades at $52.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas GSK's P/E ratio is 11.27. In terms of profitability, MIRA's ROE is -1.41%, compared to GSK's ROE of +0.24%. Regarding short-term risk, MIRA is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check GSK's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, SNY has a market cap of 104.4B. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while SNY trades at $43.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas SNY's P/E ratio is 9.47. In terms of profitability, MIRA's ROE is -1.41%, compared to SNY's ROE of +0.06%. Regarding short-term risk, MIRA is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check SNY's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, ZTS has a market cap of 31.4B. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while ZTS trades at $74.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas ZTS's P/E ratio is 11.37. In terms of profitability, MIRA's ROE is -1.41%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, MIRA is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check ZTS's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, BIIB has a market cap of 30.6B. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while BIIB trades at $207.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas BIIB's P/E ratio is 13.08. In terms of profitability, MIRA's ROE is -1.41%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, MIRA is more volatile compared to BIIB. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check BIIB's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while HZNP trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas HZNP's P/E ratio is 61.86. In terms of profitability, MIRA's ROE is -1.41%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, MIRA is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check HZNP's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, GRFS has a market cap of 6.8B. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while GRFS trades at $8.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas GRFS's P/E ratio is 9.25. In terms of profitability, MIRA's ROE is -1.41%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, MIRA is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check GRFS's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while OGN trades at $13.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas OGN's P/E ratio is 4.07. In terms of profitability, MIRA's ROE is -1.41%, compared to OGN's ROE of +0.23%. Regarding short-term risk, MIRA is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check OGN's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, CELG-RI has a market cap of 206.3M. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while CELG-RI trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, MIRA's ROE is -1.41%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, MIRA is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for MIRA.Check CELG-RI's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, CTOR has a market cap of 70.2M. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while CTOR trades at $0.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas CTOR's P/E ratio is -1.61. In terms of profitability, MIRA's ROE is -1.41%, compared to CTOR's ROE of -0.99%. Regarding short-term risk, MIRA is more volatile compared to CTOR. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check CTOR's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, SCLXW has a market cap of 58.9M. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while SCLXW trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas SCLXW's P/E ratio is -0.01. In terms of profitability, MIRA's ROE is -1.41%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, MIRA is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for MIRA.Check SCLXW's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, SCLX has a market cap of 56.8M. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while SCLX trades at $6.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas SCLX's P/E ratio is -0.17. In terms of profitability, MIRA's ROE is -1.41%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, MIRA is more volatile compared to SCLX. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check SCLX's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while BDSIW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, MIRA's ROE is -1.41%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, MIRA is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for MIRA.Check BDSIW's competition here

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRA stands at 32.2M. In comparison, CRXT has a market cap of 0. Regarding current trading prices, MIRA is priced at $0.77 on the NASDAQ, while CRXT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRA currently has a P/E ratio of -0.53, whereas CRXT's P/E ratio is -0.02. In terms of profitability, MIRA's ROE is -1.41%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, MIRA is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for MIRA.Check CRXT's competition here